{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:37:12Z","timestamp":1795091832641,"version":"4.10.2"},"reference-count":85,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":778,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s13311-021-01133-3","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T13:02:41Z","timestamp":1635339761000},"page":"1432-1444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Natural History Studies and Clinical Trial Readiness for Genetic Developmental and Epileptic Encephalopathies"],"prefix":"10.1016","volume":"18","author":[{"given":"Elizabeth E.","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid E.","family":"Scheffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1007\/s13311-021-01133-3_bib1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia."},{"key":"10.1007\/s13311-021-01133-3_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejpn.2019.12.023","article-title":"Deciphering the concepts behind \u201cEpileptic encephalopathy\u201d and \u201cDevelopmental and epileptic encephalopathy\u201d","volume":"24","author":"Scheffer","year":"2020","journal-title":"Eur J Paediatr Neurol."},{"issue":"3","key":"10.1007\/s13311-021-01133-3_bib3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41431-018-0299-8","article-title":"The role of recessive inheritance in early-onset epileptic encephalopathies: a combined whole-exome sequencing and copy number study","volume":"27","author":"Papuc","year":"2019","journal-title":"Eur J Hum Genet."},{"key":"10.1007\/s13311-021-01133-3_bib4","doi-asserted-by":"crossref","unstructured":"Symonds JD, Zuberi SM, Stewart K, McLellan A, O'Regan M, MacLeod S, Jollands A, Joss S, Kirkpatrick M, Brunklaus A, Pilz DT, Shetty J, Dorris L, Abu-Arafeh I, Andrew J, Brink P, Callaghan M, Cruden J, Diver LA, Findlay C, Gardiner S, Grattan R, Lang B, MacDonnell J, McKnight J, Morrison CA, Nairn L, Slean MM, Stephen E, Webb A, Vincent A, Wilson M. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain. August 2019;142(8):2303\u20132318. https:\/\/doi.org\/10.1093\/brain\/awz195.","DOI":"10.1093\/brain\/awz195"},{"issue":"3","key":"10.1007\/s13311-021-01133-3_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14737159.2019.1573144","article-title":"From next-generation sequencing to targeted treatment of non-acquired epilepsies","volume":"19","author":"M\u00f8ller","year":"2019","journal-title":"Expert Rev Mol Diagn."},{"issue":"7","key":"10.1007\/s13311-021-01133-3_bib6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3390\/genes12071051","article-title":"Epilepsy Syndromes in the First Year of Life and Usefulness of Genetic Testing for Precision Therapy","volume":"12","author":"Bayat","year":"2021","journal-title":"Genes (Basel)."},{"issue":"13","key":"10.1007\/s13311-021-01133-3_bib7","doi-asserted-by":"crossref","first-page":"e1770","DOI":"10.1212\/WNL.0000000000011655","article-title":"Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies","volume":"96","author":"Palmer","year":"2021","journal-title":"Neurology."},{"issue":"9","key":"10.1007\/s13311-021-01133-3_bib8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1212\/WNL.0000000000004284","article-title":"Profile of neonatal epilepsies: Characteristics of a prospective US cohort","volume":"89","author":"Shellhaas","year":"2017","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01133-3_bib9","doi-asserted-by":"crossref","unstructured":"Howell KB, Eggers S, Dalziel K, Riseley J, Mandelstam S, Myers CT, McMahon JM, Schneider A, Carvill GL, Mefford HC. Victorian Severe Epilepsy of Infancy Study Group, Scheffer IE, Harvey AS. A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy. Epilepsia. 2018 Jun; 59(6):1177-87. https:\/\/doi.org\/10.1111\/epi.14087. Epub 2018 May 11. PMID: 29750358; PMCID: PMC5990455.","DOI":"10.1111\/epi.14087"},{"key":"10.1007\/s13311-021-01133-3_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejpn.2019.12.008","article-title":"Epilepsy and developmental disorders: Next generation sequencing in the clinic","volume":"24","author":"Symonds","year":"2020","journal-title":"Eur J Paediatr Neurol."},{"key":"10.1007\/s13311-021-01133-3_bib11","doi-asserted-by":"crossref","unstructured":"Jakobsen AV, Moller RS, Nikanorova M, Elklit A. The impact of severe pediatric epilepsy on experienced stress and psychopathology in parents. Epilepsy Behav. 2020;113:107538.","DOI":"10.1016\/j.yebeh.2020.107538"},{"issue":"4","key":"10.1007\/s13311-021-01133-3_bib12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.spen.2017.10.001","article-title":"Cognitive and Social Outcomes of Epileptic Encephalopathies","volume":"24","author":"Nickels","year":"2017","journal-title":"Semin Pediatr Neurol."},{"key":"10.1007\/s13311-021-01133-3_bib13","doi-asserted-by":"crossref","unstructured":"Nevin S, Wakefield CE, Schilstra C, McGill BC, Bye A, Palmer EE. The information needs of parents of children with severe early-onset epilepsy (SEE): A systematic review. 2020;112:107382","DOI":"10.1016\/j.yebeh.2020.107382"},{"issue":"7","key":"10.1007\/s13311-021-01133-3_bib14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1001\/archneurol.2011.3275","article-title":"Progressive gait deterioration in adolescents with Dravet syndrome","volume":"69","author":"Rodda","year":"2012","journal-title":"Arch Neurol."},{"key":"10.1007\/s13311-021-01133-3_bib15","doi-asserted-by":"crossref","unstructured":"Cooper MS, Mcintosh A, Crompton DE, McMahon JM, Schneider A, Farrell K, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016 Oct 26;128:43\u201347.","DOI":"10.1016\/j.eplepsyres.2016.10.006"},{"issue":"4","key":"10.1007\/s13311-021-01133-3_bib16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/epi.16468","article-title":"Mortality in infantile spasms: A hospital-based study","volume":"61","author":"Harini","year":"2020","journal-title":"Epilepsia."},{"issue":"6","key":"10.1007\/s13311-021-01133-3_bib17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ana.25619","article-title":"Genetic Landscape of Epilepsy of Infancy with Migrating Focal Seizures","volume":"86","author":"Burgess","year":"2019","journal-title":"Ann Neurol."},{"issue":"3","key":"10.1007\/s13311-021-01133-3_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1474-4422(15)00250-1","article-title":"The genetic landscape of the epileptic encephalopathies of infancy and childhood","volume":"15","author":"McTague","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-021-01133-3_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pediatrneurol.2020.01.015","article-title":"Infantile Spasms: Outcome in Clinical Studies","volume":"108","author":"Riikonen","year":"2020","journal-title":"Pediatr Neurol."},{"issue":"10","key":"10.1007\/s13311-021-01133-3_bib20","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1212\/WNL.0000000000002457","article-title":"STXBP1 encephalopathy: A neurodevelopmental disorder including epilepsy","volume":"86","author":"Stamberger","year":"2016","journal-title":"Neurology."},{"issue":"12","key":"10.1007\/s13311-021-01133-3_bib21","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1474-4422(15)00199-4","article-title":"A roadmap for precision medicine in the epilepsies","volume":"14","author":"Consortium E","year":"2015","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1007\/s13311-021-01133-3_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14737159.2019.1573144","article-title":"From next-generation sequencing to targeted treatment of non-acquired epilepsies","volume":"19","author":"Moller","year":"2019","journal-title":"Expert Rev Mol Diagn."},{"issue":"20","key":"10.1007\/s13311-021-01133-3_bib23","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of Intraventricular Cerliponase Alfa for CLN2 Disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1007\/s13311-021-01133-3_bib24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s13311-020-00835-4","article-title":"From Genetic Testing to Precision Medicine in Epilepsy","volume":"17","author":"Striano","year":"2020","journal-title":"Neurotherapeutics."},{"issue":"4","key":"10.1007\/s13311-021-01133-3_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/13543784.2020.1743678","article-title":"Epilepsy: key experimental therapeutics in early clinical development","volume":"29","author":"Steriade","year":"2020","journal-title":"Expert Opin Investig Drugs."},{"key":"10.1007\/s13311-021-01133-3_bib26","doi-asserted-by":"crossref","unstructured":"Steriade C, French J, Devinsky O. Epilepsy: key experimental therapeutics in early clinical development. Expert Opin Investig Drugs. 2020 Apr;29(4):373\u201383.","DOI":"10.1080\/13543784.2020.1743678"},{"key":"10.1007\/s13311-021-01133-3_bib27","unstructured":"Susannah Ahern GS, Mark Tacey, Michael Esler, John Oldroyd, Joanna Dean SBobotACFD, Registry. The Australian Cystic Fibrosis Data Registry Annual Report, 2015.\u00a0Monash University, Department of Epidemiology and Preventive Medicine; 2017."},{"issue":"4","key":"10.1007\/s13311-021-01133-3_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JND-190428","article-title":"One Year of Newborn Screening for SMA - Results of a German Pilot Project","volume":"6","author":"Vill","year":"2019","journal-title":"J Neuromuscul Dis."},{"issue":"6","key":"10.1007\/s13311-021-01133-3_bib29","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","article-title":"Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group","volume":"18","author":"Richter","year":"2015","journal-title":"Value Health."},{"key":"10.1007\/s13311-021-01133-3_bib30","unstructured":"In: Field MJ, Boat TF, editors. Rare Diseases and Orphan Products: Accelerating Research and Development. The National Academies Collection: Reports funded by National Institutes of Health. Washington (DC)2010."},{"issue":"1","key":"10.1007\/s13311-021-01133-3_bib31","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13023-020-01514-5","article-title":"FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development","volume":"15","author":"Miller","year":"2020","journal-title":"Orphanet J Rare Dis."},{"issue":"8","key":"10.1007\/s13311-021-01133-3_bib32","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1517\/21678707.2015.1063415","article-title":"The importance of natural histories for rare diseases","volume":"3","author":"Gavin","year":"2015","journal-title":"Expert Opinions Orphan Drugs."},{"issue":"1","key":"10.1007\/s13311-021-01133-3_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jimd.12304","article-title":"Quantitative retrospective natural history modeling for orphan drug development","volume":"44","author":"Garbade","year":"2021","journal-title":"Journal of inherited metabolic disease."},{"key":"10.1007\/s13311-021-01133-3_bib34","doi-asserted-by":"crossref","unstructured":"Sullivan J, Scheffer IE, Lagae L, Nabbout R, Pringsheim M, Talwar D, et al. Fenfluramine HCl (Fintepla\u00ae ) provides long\u2010term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open\u2010label extension study. Epilepsia. 2020 Nov;61(11):2396\u20102404. https:\/\/doi.org\/10.1111\/epi.16722. Epub 2020 Oct 19. PMID: 33078386; PMCID:PMC7756901.","DOI":"10.1111\/epi.16722"},{"issue":"3","key":"10.1007\/s13311-021-01133-3_bib35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejmg.2010.12.001","article-title":"Care for patients with ultra-rare disorders","volume":"54","author":"Hennekam","year":"2011","journal-title":"Eur J Med Genet."},{"issue":"6","key":"10.1007\/s13311-021-01133-3_bib36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jval.2015.08.006","article-title":"Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force","volume":"18","author":"Walton","year":"2015","journal-title":"Value Health."},{"issue":"1","key":"10.1007\/s13311-021-01133-3_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13023-017-0718-x","article-title":"Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures","volume":"12","author":"Morel","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"10.1007\/s13311-021-01133-3_bib38","doi-asserted-by":"crossref","unstructured":"McKeon G, Palmer EE, Macintosh R, Nevin SM, Wheatley L, Rosenbaum S. Feasibility of a mental health informed physical activity intervention for the carers of children with developmental and epileptic encephalopathy. Epilepsy Behav. 2021;121(Pt A):108022.","DOI":"10.1016\/j.yebeh.2021.108022"},{"issue":"12","key":"10.1007\/s13311-021-01133-3_bib39","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/humu.23619","article-title":"Relationship of electrophysiological dysfunction and clinical severity in SCN2A-related epilepsies","volume":"39","author":"Lauxmann","year":"2018","journal-title":"Hum Mutat."},{"issue":"24","key":"10.1007\/s13311-021-01133-3_bib40","doi-asserted-by":"crossref","first-page":"E5516","DOI":"10.1073\/pnas.1800077115","article-title":"Dynamic action potential clamp predicts functional separation in mild familial and severe de novo forms of SCN2A epilepsy","volume":"115","author":"Berecki","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-021-01133-3_bib41","doi-asserted-by":"crossref","unstructured":"Ben-Shalom R, Keeshen CM, Berrios KN, An JY, Sanders SJ, Bender KJ. Opposing Effects on NaV1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures. Biol Psychiatry. 2017;82(3):224\u201332.","DOI":"10.1016\/j.biopsych.2017.01.009"},{"issue":"5","key":"10.1007\/s13311-021-01133-3_bib42","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/brain\/awx054","article-title":"Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders","volume":"140","author":"Wolff","year":"2017","journal-title":"Brain."},{"key":"10.1007\/s13311-021-01133-3_bib43","doi-asserted-by":"crossref","unstructured":"Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus. A genetic disorder with heterogeneous clinical phenotypes. Brain. 1997;120 (Pt 3):479\u201390.","DOI":"10.1093\/brain\/120.3.479"},{"issue":"9","key":"10.1007\/s13311-021-01133-3_bib44","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1111\/epi.13071","article-title":"Mutations in KCNT1 cause a spectrum of focal epilepsies","volume":"56","author":"Moller","year":"2015","journal-title":"Epilepsia."},{"key":"10.1007\/s13311-021-01133-3_bib45","doi-asserted-by":"crossref","unstructured":"Palmer EE. Potassium Channel Mutations in Epilepsy. The Oxford Handbook of Neuronal Ion Channels. Edited by Arin Bhattacharjee. Subject: Neuroscience, Molecular and Cellular Systems. Online Publication Date: Aug 2020. https:\/\/doi.org\/10.1093\/oxfordhb\/9780190669164.013.13.","DOI":"10.1093\/oxfordhb\/9780190669164.013.13"},{"issue":"1","key":"10.1007\/s13311-021-01133-3_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11011-020-00635-x","article-title":"Epilepsy in inherited neurotransmitter disorders: Spotlights on pathophysiology and clinical management","volume":"36","author":"Mastrangelo","year":"2021","journal-title":"Metab Brain Dis."},{"issue":"4","key":"10.1007\/s13311-021-01133-3_bib47","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.20029","article-title":"Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy","volume":"55","author":"Berkovic","year":"2004","journal-title":"Ann Neurol."},{"issue":"1","key":"10.1007\/s13311-021-01133-3_bib48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41398-020-0803-0","article-title":"A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy","volume":"10","author":"Kolc","year":"2020","journal-title":"Transl Psychiatry."},{"issue":"6","key":"10.1007\/s13311-021-01133-3_bib49","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40256-016-0203-2","article-title":"Sebelipase Alfa: A Review in Lysosomal Acid Lipase Deficiency","volume":"16","author":"Frampton","year":"2016","journal-title":"Am J Cardiovasc Drugs."},{"issue":"10","key":"10.1007\/s13311-021-01133-3_bib50","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.5664\/jcsm.7376","article-title":"Randomized Controlled Trial of Melatonin for Sleep Disturbance in Dravet Syndrome: The DREAMS Study","volume":"14","author":"Myers","year":"2018","journal-title":"J Clin Sleep Med."},{"key":"10.1007\/s13311-021-01133-3_bib51","doi-asserted-by":"crossref","unstructured":"Moavero R, Benvenuto A, Emberti Gialloreti L, Siracusano M, Kotulska K, Weschke B, et al. Early Clinical Predictors of Autism Spectrum Disorder in Infants with Tuberous Sclerosis Complex: Results from the EPISTOP Study. J Clin Med. 2019;8(6).","DOI":"10.3390\/jcm8060788"},{"issue":"10","key":"10.1007\/s13311-021-01133-3_bib52","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/dmcn.14186","article-title":"Perception of impact of Dravet syndrome on children and caregivers in multiple countries: looking beyond seizures","volume":"61","author":"Nabbout","year":"2019","journal-title":"Dev Med Child Neurol."},{"issue":"2","key":"10.1007\/s13311-021-01133-3_bib53","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/WCO.0000000000000533","article-title":"Are the days of counting seizures numbered?","volume":"31","author":"Karoly","year":"2018","journal-title":"Curr Opin Neurol."},{"issue":"3","key":"10.1007\/s13311-021-01133-3_bib54","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ana.24470","article-title":"Confusing placebo effect with natural history in epilepsy: A big data approach","volume":"78","author":"Goldenholz","year":"2015","journal-title":"Ann Neurol."},{"issue":"1","key":"10.1007\/s13311-021-01133-3_bib55","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/archdischild-2014-306400","article-title":"Limited role for routine EEG in the assessment of staring in children with autism spectrum disorder","volume":"100","author":"Hughes","year":"2015","journal-title":"Arch Dis Child."},{"issue":"4","key":"10.1007\/s13311-021-01133-3_bib56","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejpn.2016.04.005","article-title":"Epilepsy is not a mandatory feature of STXBP1 associated ataxia-tremor-retardation syndrome","volume":"20","author":"Gburek-Augustat","year":"2016","journal-title":"Eur J Paediatr Neurol."},{"issue":"1","key":"10.1007\/s13311-021-01133-3_bib57","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1212\/WNL.0000000000004769","article-title":"Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine","volume":"90","author":"Mullen","year":"2018","journal-title":"Neurology."},{"issue":"7","key":"10.1007\/s13311-021-01133-3_bib58","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMc1708349","article-title":"Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome","volume":"377","author":"Devinsky","year":"2017","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1007\/s13311-021-01133-3_bib59","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(05)70199-X","article-title":"The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial","volume":"4","author":"Lux","year":"2005","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1007\/s13311-021-01133-3_bib60","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.25956","article-title":"Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial","volume":"89","author":"Kotulska","year":"2021","journal-title":"Ann Neurol."},{"issue":"1","key":"10.1007\/s13311-021-01133-3_bib61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1866-1955-6-16","article-title":"Improving IQ measurement in intellectual disabilities using true deviation from population norms","volume":"6","author":"Sansone","year":"2014","journal-title":"J Neurodev Disord."},{"key":"10.1007\/s13311-021-01133-3_bib62","doi-asserted-by":"crossref","unstructured":"Berg AT, Palac H, Wilkening G, Zelko F, Schust Meyer L. SCN2A-Developmental and Epileptic Encephalopathies: Challenges to trial-readiness for non-seizure outcomes. Epilepsia. 2021 Jan;62(1):258\u201368.","DOI":"10.1111\/epi.16750"},{"key":"10.1007\/s13311-021-01133-3_bib63","doi-asserted-by":"crossref","unstructured":"Sadhwani A, Wheeler A, Gwaltney A, Peters SU, Barbieri-Welge RL, Horowitz LT, et al. Developmental Skills of Individuals with Angelman Syndrome Assessed Using the Bayley-III. J Autism Dev Disord. 2021; https:\/\/doi.org\/10.1007\/s10803-020-04861-1.","DOI":"10.1007\/s10803-020-04861-1"},{"issue":"11","key":"10.1007\/s13311-021-01133-3_bib64","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1177\/08830738211019576","article-title":"Content Validation of Clinician-Reported Items for a Severity Measure for CDKL5 Deficiency Disorder","volume":"36","author":"Saldaris","year":"2021","journal-title":"J Child Neurol."},{"key":"10.1007\/s13311-021-01133-3_bib65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pediatrneurol.2019.03.017","article-title":"Severity Assessment in CDKL5 Deficiency Disorder","volume":"97","author":"Demarest","year":"2019","journal-title":"Pediatr Neurol."},{"issue":"8","key":"10.1007\/s13311-021-01133-3_bib66","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1111\/epi.16285","article-title":"CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development","volume":"60","author":"Demarest","year":"2019","journal-title":"Epilepsia."},{"issue":"2\u20133","key":"10.1007\/s13311-021-01133-3_bib67","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.eplepsyres.2008.01.007","article-title":"The Early Childhood Epilepsy Severity Scale (E-Chess)","volume":"79","author":"Humphrey","year":"2008","journal-title":"Epilepsy Res."},{"issue":"2","key":"10.1007\/s13311-021-01133-3_bib68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/dmcn.13601","article-title":"Sleep problems in Dravet syndrome: a modifiable comorbidity","volume":"60","author":"Licheni","year":"2018","journal-title":"Dev Med Child Neurol."},{"key":"10.1007\/s13311-021-01133-3_bib69","doi-asserted-by":"crossref","unstructured":"Hanratty J, Livingstone N, Robalino S, Terwee CB, Glod M, Oono IP, et al. Systematic Review of the Measurement Properties of Tools Used to Measure Behaviour Problems in Young Children with Autism. PLoS One. 2015;10(12):e0144649.","DOI":"10.1371\/journal.pone.0144649"},{"key":"10.1007\/s13311-021-01133-3_bib70","doi-asserted-by":"crossref","unstructured":"Randall M, Egberts KJ, Samtani A, Scholten RJ, Hooft L, Livingstone N, et al. Diagnostic tests for autism spectrum disorder (ASD) in preschool children. Cochrane Database Syst Rev. 2018;7:CD009044.","DOI":"10.1002\/14651858.CD009044.pub2"},{"key":"10.1007\/s13311-021-01133-3_bib71","doi-asserted-by":"crossref","unstructured":"Bruni O, Ottaviano S, Guidetti V, Romoli M, Innocenzi M, Cortesi F, et al. The Sleep Disturbance Scale for Children (SDSC). Construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence. J Sleep Res. 1996;5(4):251\u201361.","DOI":"10.1111\/j.1365-2869.1996.00251.x"},{"issue":"6","key":"10.1007\/s13311-021-01133-3_bib72","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/epi.13000","article-title":"Development and assessment of a shortened Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55)","volume":"56","author":"Goodwin","year":"2015","journal-title":"Epilepsia."},{"key":"10.1007\/s13311-021-01133-3_bib73","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nbd.2018.05.007","article-title":"Epilepsy biomarkers - Toward etiology and pathology specificity","volume":"123","author":"Pitkanen","year":"2019","journal-title":"Neurobiol Dis."},{"key":"10.1007\/s13311-021-01133-3_bib74","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eplepsyres.2015.07.008","article-title":"Improving the inter-rater agreement of hypsarrhythmia using a simplified EEG grading scale for children with infantile spasms","volume":"116","author":"Mytinger","year":"2015","journal-title":"Epilepsy Res."},{"issue":"6","key":"10.1007\/s13311-021-01133-3_bib75","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.braindev.2014.10.003","article-title":"Electroencephalographic features of patients with SCN1A-positive Dravet syndrome","volume":"37","author":"Lee","year":"2015","journal-title":"Brain Dev."},{"issue":"17","key":"10.1007\/s13311-021-01133-3_bib76","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1212\/WNL.0000000000003868","article-title":"Impaired intracortical inhibition demonstrated in vivo in people with Dravet syndrome","volume":"88","author":"Stern","year":"2017","journal-title":"Neurology."},{"issue":"6","key":"10.1007\/s13311-021-01133-3_bib77","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2174\/1389201019666180713095251","article-title":"Diagnostic Biomarkers of Epilepsy","volume":"19","author":"Sueri","year":"2018","journal-title":"Curr Pharm Biotechnol."},{"issue":"1","key":"10.1007\/s13311-021-01133-3_bib78","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1535759719827430","article-title":"Are Seizure Detection Devices Ready for Prime Time?","volume":"19","author":"Van Ness","year":"2019","journal-title":"Epilepsy Curr."},{"key":"10.1007\/s13311-021-01133-3_bib79","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3389\/fneur.2019.00898","article-title":"Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy","volume":"10","author":"Kariyawasam","year":"2019","journal-title":"Front Neurol."},{"key":"10.1007\/s13311-021-01133-3_bib80","unstructured":"Blattner-Johnson M, Jones DTW, Pfaff E. Precision medicine in pediatric solid cancers. Semin Cancer Biol. 2021;S1044-579X(21)00178-4."},{"issue":"1","key":"10.1007\/s13311-021-01133-3_bib81","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1038\/s41467-020-17090-y","article-title":"Predicting and affecting response to cancer therapy based on pathway-level biomarkers","volume":"11","author":"Ben-Hamo","year":"2020","journal-title":"Nat Commun."},{"issue":"11","key":"10.1007\/s13311-021-01133-3_bib82","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/s41591-020-1072-4","article-title":"Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer","volume":"26","author":"Wong","year":"2020","journal-title":"Nature medicine."},{"issue":"12","key":"10.1007\/s13311-021-01133-3_bib83","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1080\/15384047.2018.1491498","article-title":"Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer","volume":"19","author":"Tsoli","year":"2018","journal-title":"Cancer Biol Ther."},{"issue":"1","key":"10.1007\/s13311-021-01133-3_bib84","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cts.12500","article-title":"Future of Rare Diseases Research 2017\u20132027: An IRDiRC Perspective","volume":"11","author":"Austin","year":"2018","journal-title":"Clin Transl Sci."},{"issue":"2","key":"10.1007\/s13311-021-01133-3_bib85","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/dmcn.13601","article-title":"Sleep problems in Dravet syndrome: a modifiable comorbidity","volume":"60","author":"Licheni","year":"2018","journal-title":"Dev Med Child Neurol."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01133-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:50:05Z","timestamp":1761807005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923007456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1878747923007456"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01133-3","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural History Studies and Clinical Trial Readiness for Genetic Developmental and Epileptic Encephalopathies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01133-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}